Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) was upgraded by equities research analysts at JMP Securities from a “market perform” rating to a “market outperform” rating in a research report issued on Monday,Benzinga reports. The brokerage presently has a $33.00 price objective on the stock. JMP Securities’ target price indicates a potential upside of 65.33% from the company’s previous close.
Several other research firms have also weighed in on NTLA. Royal Bank Of Canada decreased their target price on shares of Intellia Therapeutics from $25.00 to $21.00 and set an “outperform” rating on the stock in a report on Friday, August 8th. Wells Fargo & Company reiterated an “overweight” rating and issued a $45.00 price objective (down from $50.00) on shares of Intellia Therapeutics in a report on Friday, August 8th. HC Wainwright raised their target price on Intellia Therapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, September 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Saturday, September 27th. Finally, Wall Street Zen raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 6th. Twelve investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.68.
View Our Latest Stock Report on NTLA
Intellia Therapeutics Stock Performance
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The business had revenue of $14.25 million for the quarter, compared to analyst estimates of $12.26 million. During the same quarter in the previous year, the firm earned ($1.52) EPS. The company’s quarterly revenue was up 104.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Intellia Therapeutics will post -5.07 EPS for the current year.
Insider Buying and Selling at Intellia Therapeutics
In other Intellia Therapeutics news, CAO Michael P. Dube sold 1,871 shares of Intellia Therapeutics stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total transaction of $32,517.98. Following the completion of the sale, the chief accounting officer directly owned 55,266 shares of the company’s stock, valued at $960,523.08. The trade was a 3.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director William J. Chase bought 100,000 shares of the business’s stock in a transaction dated Wednesday, August 20th. The shares were acquired at an average cost of $10.03 per share, for a total transaction of $1,003,000.00. Following the transaction, the director directly owned 134,693 shares in the company, valued at approximately $1,350,970.79. This represents a 288.24% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 9,364 shares of company stock worth $137,674 over the last ninety days. Corporate insiders own 3.10% of the company’s stock.
Institutional Trading of Intellia Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the company. Cambridge Investment Research Advisors Inc. increased its position in Intellia Therapeutics by 51.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 19,726 shares of the company’s stock worth $140,000 after buying an additional 6,722 shares during the period. D.A. Davidson & CO. increased its holdings in shares of Intellia Therapeutics by 76.2% in the 1st quarter. D.A. Davidson & CO. now owns 26,020 shares of the company’s stock valued at $185,000 after acquiring an additional 11,250 shares during the period. Voya Investment Management LLC raised its position in Intellia Therapeutics by 621.5% in the 1st quarter. Voya Investment Management LLC now owns 208,009 shares of the company’s stock valued at $1,479,000 after purchasing an additional 179,180 shares during the last quarter. California State Teachers Retirement System boosted its stake in Intellia Therapeutics by 4.1% during the 4th quarter. California State Teachers Retirement System now owns 90,638 shares of the company’s stock worth $1,057,000 after purchasing an additional 3,596 shares during the period. Finally, Ballentine Partners LLC purchased a new position in Intellia Therapeutics during the 2nd quarter worth $161,000. 88.77% of the stock is owned by hedge funds and other institutional investors.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Read More
- Five stocks we like better than Intellia Therapeutics
- Golden Cross Stocks: Pattern, Examples and Charts
- Get the Best Bang for Your Buck: 3 Low-Cost, High-Return ETFs
- 3 Defense Stocks Set to Benefit From Increased Military Spending
- 3 Cybersecurity Stocks Poised for Long-Term Growth
- How to Profit From Value Investing
- 3 Defense Stocks Surging as Ukraine Tensions Deepen
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.